AbCellera Biologics (ABCL) Intangibles (2020 - 2026)

AbCellera Biologics has reported Intangibles for 7 years, with the latest figure at $37.5 million in Q1 2026.

• For the quarter ending Q1 2026, Intangibles fell 9.06% year-over-year to $37.5 million; the trailing twelve-month figure through Mar 2026 stood at $37.5 million (down 9.06% YoY), and the FY2025 full-year result was $38.4 million, down 8.86% from the prior year.
• Intangibles for Q1 2026 stood at $37.5 million, down from $38.4 million in the prior quarter.
• The five-year high for Intangibles was $163.0 million in Q3 2022, with the low at $37.5 million in Q1 2026.
• Historically, Intangibles has averaged $93.8 million across 5 years, with a median of $118.7 million in 2024.
• Annual changes were most pronounced in 2022 — Intangibles soared 310.94% — and 2025, when it slumped 65.31%.
• AbCellera Biologics' Intangibles stood at $131.5 million in 2022, then decreased by 8.42% to $120.4 million in 2023, then plunged by 65.03% to $42.1 million in 2024, then slipped by 8.86% to $38.4 million in 2025, then slipped by 2.4% to $37.5 million in 2026.
• The last three Intangibles figures came in at $37.5 million (Q1 2026), $38.4 million (Q4 2025), and $39.3 million (Q3 2025), per Business Quant data.